来氟米特治疗前后强直性脊柱炎血清IL-12及IL-15水平变化

The changes of IL-12 and IL-15 levels in serum of patieuts with ankylosing spondylitis following the treatment of leflunomide

目的探讨来氟米特(LEF)对强直性脊柱炎(AS)血清白细胞介素-12(IL-12)及白细胞介素-15(IL-15)的影响。方法2004-03～2007-03采用LEF治疗活动性AS34例,ELISA方法检测治疗前后血清IL-12、IL-15水平,并进行比较。结果34例AS患者,血清IL-12治疗前后的含量分别为(5.68±0.77)和(5.03±0.62)pg/ml,IL-15治疗前后的含量分别为(11.12±4.68)和(9.32±3.02)pg/ml。结论LEF能够降低AS患者血清IL-12和IL-15的水平,可能是LEF治疗AS的机制之一。

Objective To investigate the impacts of leflunomide on IL-12 and -15 levels in serum of patients with ankylosing spondylitis （AS）. Method From March of 2004 to March of 2007, 34 cases of ankylosing spondylitis were treated with leflunomide（LEF）. The levels of IL-12 and IL-15 in their serum before and after treatment were measured by enzyme-linked immunosorbent assay （ELISN）. Result The serum level of IL-12 before and after treatment was 5.68±0.77pg/ml and 5.03±0.62pg/ml, respectively; of IL-15 were 11.12±4.68pg/ml and 9.32±3.02pg/ml, respectively. Conclusion LEF could reduce the serum levels of IL-12 and -15, thus which could be one of the mechanism of therapy for AS.